OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

BERLIN BOSTON–(BUSINESS WIRE)–OMEICOS Therapeutics, a biopharmaceutical company developing
first-in-class small molecule therapeutics for the prevention and
treatment of cardiovascular and ophthalmic diseases, today announced the
appointment of Christian Schetter, Ph.D., as an independent Board
Member. Christian has over 20 years’ industry experience across the life
sciences sector, and most recently joined venture capital firm Arix
Bioscience plc as an Entrepreneur in Residence. Before that he was
instrumental in building German immuno-oncology company Rigontec GmbH as
their CEO and managed the integration process after Rigontec was
acquired by MSD in 2017. His appointment adds a second independent board
member to the OMEICOS board complementing the position of Dr. Bernd
Kirschbaum as Chairman of the Supervisory Board.

Dr. Bernd Kirschbaum, Chairman of the Supervisory Board commented:
“Bringing Christian on board, an experience leader who has gone through
the process of building up biopharmaceutical start-ups, delivering on
the important value inflection points in RD and taking the next steps
in corporate development, adds valuable expertise to the OMEICOS board.
With two independent board members, in addition to the experienced board
representation from our investors already in place, OMEICOS is well
equipped for the next corporate development steps.”

“We welcome Christian to our Supervisory Board and are looking forward
to working with him as OMEICOS enters a very exciting stage in its
development. Christian’s appointment adds a second independent board
member to our team, following Bernd Kirschbaum’s addition to the board
in 2015 whose years of RD leadership at pharmaceutical companies have
been and will continue to be essential as we advance our lead compound
in Atrial Fibrillation towards proof-of-concept in patients and continue
expanding our development pipeline with our subsidiary OMEICOS
Ophthalmics in Boston. Taken together, Bernd and Christian bring two
unique sets of experience and expertise to OMEICOS,” added Robert
Fischer, MD, CEO/CSO of OMEICOS Therapeutics.

Prior to his role at Rigontec GmbH, Christian was President and CEO of
Neovii Biotech (previously Fresenius Biotech). During his tenure, one
antibody product was brought to market and the indication for another
product expanded. Christian was also instrumental in selling Fresenius
Biotech to the Neopharm Group, Israel, to form Neovii Biotech and
positioning it as a successful standalone business. He was SVP of
European Operations at Coley Pharmaceutical Group and Managing Director
of Coley GmbH. Christian was part of the leadership team which built
Coley Pharmaceuticals from inception through multiple financing rounds,
a NASDAQ IPO and, following several significant pharma deals, to a trade
sale to Pfizer in 2007. Before entering the life science industry,
Christian was successfully performing academic research at the Max
Planck Institute in Martinsried, Germany. He received his undergraduate
degree and PhD from the University of Cologne and did postdoctoral
research in oncology and virology at the Scripps Research Institute in
La Jolla, California.

About OMEICOS

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center
for Molecular Medicine (MDC) in Berlin. The company has discovered a
series of metabolically robust synthetic analogues of omega-3 fatty
acid-derived epoxyeicosanoids that have the potential to treat
inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a
newly described class of bioactive lipid mediators, activate cell
type-specific endogenous pathways that promote organ and tissue
protection. OMEICOS’ small molecules are orally available and show
improved biological activity and pharmacokinetic properties compared to
their natural counterparts. OMEICOS’ technology is based on
ground-breaking scientific results in the field of omega-3 fatty acid
metabolism and physiology obtained by the companies’ founders, Dr.
Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr.
Robert Fischer. The companies’ research activities are supported by a
grant from the German Ministry of Education and Research (BMBF). www.omeicos.com

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced its expansion in mainland
China through a licensing agreement with C-Bridge Capital. The agreement
covers multiple biosimilar candidates from Samsung Bioepis, including
third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS®
(ranibizumab) and SOLIRIS® (eculizumab), respectively, as
well as SB3, a biosimilar candidate referencing HERCEPTIN® 3
(trastuzumab).

Under the agreement, C-Bridge will establish a new biopharmaceutical
company, AffaMed Therapeutics, which will collaborate with Samsung
Bioepis across a number of areas, including clinical development,
regulatory registration and commercialization in China. Samsung Bioepis
will receive an upfront payment, as well as royalties on sales.
Additional financial details were not disclosed.

“We want to play an important role in widening access to high-quality
healthcare for patients throughout China. C-Bridge is the right partner
for this mission as evidenced in its exceptional track record of
successfully turning portfolio companies like AffaMed Therapeutics into
leading biopharmaceutical companies in China and beyond,” said
Christopher Hansung Ko, President and Chief Executive Officer, Samsung
Bioepis. “At Samsung Bioepis, we will continue to demonstrate our
enduring commitment to biosimilars by further strengthening our pipeline
and widening their availability for patients and healthcare systems
across the world.”

Established in February 2012, Samsung Bioepis currently has four
biosimilars approved and marketed across Europe, which include the
anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab) and
IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT®
(trastuzumab). In the United States, the company has one biosimilar –
RENFLEXIS® (infliximab-abda) –.on the market, while another
biosimilar – ONTRUZANT® (trastuzumab-dttb) – has been
approved by the U.S. Food and Drug Administration (FDA). A Biologics
License Application (BLA) for SB5 (adalimumab) biosimilar candidate is
currently under review at the FDA.

In total, over 100,000 patients across the world are currently under
treatment with Samsung Bioepis’ biosimilars, with over 6 million doses
administered.

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on
identifying and licensing late stage candidates for commercialization in
emerging Asia Pacific markets and globally. AffaMed was founded and
funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused
on growth and late stage investment opportunities across healthcare
industry. C-Bridge Capital’s current portfolio includes China’s leading
players in pharmaceuticals, medical devices, diagnosis and healthcare
services. As of today, the AUM of C-Bridge Capital has exceeded US$1.8
Billion. C-Bridge Capital is committed to support commercialization of
cutting-edge technologies and companies that fulfil unmet medical needs,
thus continuously improving the standard and quality of care for
patients.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company
committed to realizing healthcare that is accessible to everyone.
Through innovations in product development and a firm commitment to
quality, Samsung Bioepis aims to become the world’s leading
biopharmaceutical company. Samsung Bioepis continues to advance a broad
pipeline of biosimilar candidates that cover a spectrum of therapeutic
areas, including immunology, oncology, ophthalmology and hematology.
Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen.
For more information, please visit: www.samsungbioepis.com.

____________________________________________

1 LUCENTIS® is a registered
trademark of Genentech

2 SOLIRIS® is a registered
trademark of Alexion

3 HERCEPTIN® is a registered
trademark of Genentech

Riassunto: Samsung Bioepis e C-Bridge Capital intendono sviluppare e commercializzare biosimilari di prossima generazione in Cina

INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. ha annunciato oggi la propria espansione nella
Cina continentale grazie alla stipula di un contratto di licenza con
C-Bridge Capital.

Il testo originale del presente annuncio, redatto nella lingua di
partenza, è la versione ufficiale che fa fede. Le traduzioni sono
offerte unicamente per comodità del lettore e devono rinviare al testo
in lingua originale, che è l’unico giuridicamente valido.

Fusion Inhibitor – Pipeline Insight, 2019

DUBLIN–(BUSINESS WIRE)–The “Fusion
Inhibitor – Pipeline Insight, 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Fusion Inhibitor – Pipeline Insight, 2019 offers
comprehensive insights of the pipeline (under development) therapeutics
scenario and growth prospects across Fusion Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and RD activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for Fusion
    Inhibitor
  • Features the Fusion Inhibitor pipeline across the complete product
    development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Fusion Inhibitor with
    key coverage of developmental activities including licensing
    collaboration deals, patent details, designations, technologies,
    indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage,
    product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Fusion
    Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline
    scenario across Fusion Inhibitor to formulate effective RD strategies
  • Assess challenges and opportunities that influence Fusion Inhibitor
    research development (RD)
  • Gather impartial perspective of strategies of the emerging competitors
    having potentially lucrative portfolio in this space and create
    effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications
    for Fusion Inhibitor
  • Identify the product attributes and use it for target finding, drug
    repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying
    prospective partners with progressing projects for Fusion Inhibitor to
    enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying
    key players in this area and their most promising pipeline
    therapeutics and developmental progress

Companies Mentioned

  • FrontierBiotech
  • Gilead Sciences
  • Bioverativ

Topics Covered

1. Report Introduction

2. Fusion Inhibitor – Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Fusion Inhibitor

4. Comparative Analysis

5. Fusion Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Fusion Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7pbv3p/fusion_inhibitor?w=4

Western Dental Partners with San Jose Mexican Consulate, Health Trust on Dental Health Program

SAN JOSE, Calif.–(BUSINESS WIRE)–Western Dental Orthodontics, one of the nation’s leaders in
accessible, affordable oral healthcare and the leading orthodontics
provider in the country, today announced an agreement with the Health
Trust and the Mexican Consulate in San Jose to be the dental health
partner in the Consulate’s Windows of Health program.

Under the partnership, Western Dental will administer the dental health
program throughout Santa Clara, Santa Cruz, San Benito and Monterey
counties.

The Health Trust will offer medical screenings and health education
workshops to patrons of the Consulate.

“We’re pleased that Western Dental and the Health Trust will be our
dental health partners in our Windows of Health program,” said Juan
Manuel Calderon Jaimes, General Consul at the Consulate. “Our
alliance strengthens the range of health services offered to the Mexican
migrant community.”

The Consulate General has designated a space for Western Dental’s use to
provide free dental screenings, dental exams and dental education for
adults and children.

Initially, dental services at the Consulate will be available for two
days each week and will be expanded as the need grows. Western Dental
will also be a full participant in upcoming health fairs at the
Consulate and in the “Mobile Consulate” program.

Among the specific services Western Dental will provide are:

  • Workshops on topics such as brushing teeth and flossing
  • Regular dental visits
  • Dental services for children, adults and seniors
  • Nutrition in oral health, oral anatomy, mouth cancer, orthodontics,
    gingivitis, and additional topics.

“Our agreement fortifies the existing relationship we’ve built with the
Consulate and will raise awareness about the importance of maintaining
good oral health,” said Edwin Rivera, Vice President of Community
Marketing Strategic Alliances for Western Dental. “We are extremely
happy to partner with the Consulate in serving the community and
providing the oral health education and dental services that are needed
in this area.”

The partnership will kick off Friday, February 8, with an inauguration
ceremony, followed with a Health Fair on February 9 at the Consulate,
located at 302 Enzo Drive, Suite 200 in San Jose.

ABOUT WESTERN DENTAL

Western Dental (with its affiliates, including Brident Dental
Orthodontics, Access Dental, Blue Hills Dental, South Texas Dental and
Vital Smiles) is one of the nation’s largest dental providers and is the
leader in accessible, affordable oral healthcare, serving approximately
2.9 million patient visits annually in 313 affiliated offices throughout
California, Texas, Arizona, Nevada and Alabama. In addition to general
dentistry, Western Dental offers orthodontics, oral surgery, pediatric
dentistry, periodontics and endodontics in its offices, creating a
convenient full service “Dental Home.”

In California, Western Dental is the leading provider of services to
both adults and children in the Denti-Cal program – part of the Medi-Cal
public insurance program that provides health care benefits for more
than 13 million low-income individuals and families. Western Dental
dentists provided care to more than a half-million Denti-Cal
beneficiaries in 2017 and is committed to continuing to partner with the
State to improve the program. In Texas, Western Dental is the leading
provider of Medicaid services and recently entered into a
first-of-its-kind agreement to participate in a value-based care and
payment model under the state’s Medicaid program.

All of Western Dental’s services are backed by a unique quality
assurance system that electronically monitors all patient visits,
treatments, dental staff and clinical performance to enable high-quality
care. To learn more about Western Dental or inquire about an office in
your community, visit www.westerndental.com
or call 1-800-6-DENTAL.

Shirley Family Office Sends Letter to PLx Pharma (PLXP) Board of Directors

LOS ANGELES–(BUSINESS WIRE)–The Shirley Family Office, which owns more than 3% of PLx Pharma Inc.
(“PLXP”) common shares, sent a letter to the Board of Directors that
criticizes the recently proposed convertible preferred stock financing
(the “CPS Financing”) as massively dilutive, asks the Board to terminate
the CPS Financing and conduct a properly marketed capital raise, and
indicates its intent to vote AGAINST the CPS Financing, which requires
shareholder approval.

The letter asserts that given the size, dilution, discounted conversion
strike price, and low implied valuation of the CPS Financing, the Board
should have structured the financing as a rights offering open to ALL
SHAREHOLDERS on a pro rata basis, rather than allow a single shareholder
to massively dilute all the rest.

The letter further asserts that the massively dilutive CPS Financing –
struck at only $2.60 per share, or a 50% discount to the current share
price, and indicating a nominal enterprise valuation of less than $15
million – reflects almost none of the potential upside highlighted in
PLXP’s public filings. These filings suggest that PLXP has developed a
revolutionary drug delivery platform and that management expects its
Vazalore aspirin products to become the new standard of care for
cardiovascular aspirin treatment, with an estimated total addressable
market of $10 billion in the United States alone. Management comments at
a recent presentation suggest a planned mid-2020 product launch and a
potential company valuation well over $1 billion if market share targets
are achieved.

Innovative Industrial Properties Acquires California Property and Enters Into Long-Term Lease with Experienced Operator

SAN DIEGO–(BUSINESS WIRE)–Innovative Industrial Properties, Inc. (IIP), the first and only real
estate company on the New York Stock Exchange (NYSE: IIPR) focused on
the regulated U.S. cannabis industry, announced today that it closed on
the acquisition of a property in Sacramento, California, which comprises
approximately 43,000 square feet of industrial space. This acquisition
marks IIP’s first investment in California and expands its portfolio to
ten U.S. states.

The purchase price for the Sacramento property was approximately $6.7
million (excluding transaction costs). Concurrent with the closing of
the purchase, IIP entered into a long-term, triple-net lease agreement
with an experienced operator, which intends to operate the property as a
licensed cannabis cultivation facility in accordance with California
regulations. The seller of the property is expected to complete
redevelopment of the building, for which IIP has agreed to provide
reimbursement of up to $4.8 million. Assuming full reimbursement for the
redevelopment, IIP’s total investment in the property will be
approximately $11.5 million.

As the pioneering real estate investment trust (REIT) for the
medical-use cannabis industry, IIP partners with experienced medical-use
cannabis operators and serves as a source of capital by acquiring and
leasing back their real estate assets, in addition to offering other
creative real estate-based capital solutions.

“We are excited to add California to our portfolio,” said Paul Smithers,
President and Chief Executive Officer of Innovative Industrial
Properties, Inc. “The tenant has a long track record of success serving
patients in need in California, and we look forward to completing the
redevelopment of the property with their team, which will enable them to
significantly expand their reach.”

The tenant has operated in the California cannabis industry for ten
years, including seven years at the property, having received its
permanent adult-use and medical-use cannabis retailer license for its
dispensary in Sacramento, as well as temporary licenses for distribution
and cultivation. The tenant expects to be issued its permanent cannabis
cultivation license at the property upon completion of the property
redevelopment.

California, with nearly 40 million residents, was the first state to
permit the use of cannabis for medicinal purposes, adopting the
Compassion Care Act in 1996. In November 2016, California voters
approved the Adult Use of Marijuana Act (Proposition 64), which permits
the sale of cannabis for adult-use, with first licenses issued in 2018.
ArcView Market Research estimates that California regulated cannabis
spending will grow from approximately $2.5 billion in 2018 to $5.6
billion in 2022, just modestly below Canada’s total estimated regulated
cannabis spending in that year of $5.9 billion.

As of February 8, 2019, IIP owned twelve properties located in Arizona,
California, Colorado, Illinois, Maryland, Massachusetts, Michigan,
Minnesota, New York and Pennsylvania, totaling approximately 1,070,000
rentable square feet (including approximately 101,000 rentable square
feet under development/redevelopment), which were 100% leased with a
weighted-average remaining lease term of approximately 14.3 years. As of
February 8, 2019, IIP had invested approximately $156.3 million in the
aggregate (excluding transaction costs) and had committed an additional
approximately $22.6 million to reimburse certain tenants and sellers for
completion of construction and tenant improvements at IIP’s properties.
IIP’s average current yield on invested capital is approximately 15.2%
for these twelve properties, calculated as (a) the sum of the current
base rents, supplemental rent (with respect to the lease with PharmaCann
LLC at one of IIP’s New York properties) and property management fees,
divided by (b) IIP’s aggregate investment in these properties (excluding
transaction costs and including aggregate potential
development/redevelopment funding and tenant reimbursements of
approximately $22.6 million).

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is a self-advised Maryland
corporation focused on the acquisition, ownership and management of
specialized industrial properties leased to experienced, state-licensed
operators for their regulated medical-use cannabis facilities.
Innovative Industrial Properties, Inc. has elected to be taxed as a real
estate investment trust, commencing with the year ended December 31,
2017. Additional information is available at www.innovativeindustrialproperties.com.

Innovative Industrial Properties
Forward-Looking Statements

This press release contains statements that IIP believes to be
“forward-looking statements” within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
statements other than historical facts, including, without limitation,
statements regarding the lease of the California property, the tenant
and the California regulated cannabis market, are forward-looking
statements. When used in this press release, words such as we “expect,”
“intend,” “plan,” “estimate,” “anticipate,” “believe” or “should” or the
negative thereof or similar terminology are generally intended to
identify forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed in, or implied by, such
statements.
Investors should not place undue reliance upon
forward-looking statements.
IIP disclaims any obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.

Innovative Industrial Properties Acquires California Property and Enters Into Long-Term Lease with Experienced Operator

SAN DIEGO–(BUSINESS WIRE)–Innovative Industrial Properties, Inc. (IIP), the first and only real
estate company on the New York Stock Exchange (NYSE: IIPR) focused on
the regulated U.S. cannabis industry, announced today that it closed on
the acquisition of a property in Sacramento, California, which comprises
approximately 43,000 square feet of industrial space. This acquisition
marks IIP’s first investment in California and expands its portfolio to
ten U.S. states.

The purchase price for the Sacramento property was approximately $6.7
million (excluding transaction costs). Concurrent with the closing of
the purchase, IIP entered into a long-term, triple-net lease agreement
with an experienced operator, which intends to operate the property as a
licensed cannabis cultivation facility in accordance with California
regulations. The seller of the property is expected to complete
redevelopment of the building, for which IIP has agreed to provide
reimbursement of up to $4.8 million. Assuming full reimbursement for the
redevelopment, IIP’s total investment in the property will be
approximately $11.5 million.

As the pioneering real estate investment trust (REIT) for the
medical-use cannabis industry, IIP partners with experienced medical-use
cannabis operators and serves as a source of capital by acquiring and
leasing back their real estate assets, in addition to offering other
creative real estate-based capital solutions.

“We are excited to add California to our portfolio,” said Paul Smithers,
President and Chief Executive Officer of Innovative Industrial
Properties, Inc. “The tenant has a long track record of success serving
patients in need in California, and we look forward to completing the
redevelopment of the property with their team, which will enable them to
significantly expand their reach.”

The tenant has operated in the California cannabis industry for ten
years, including seven years at the property, having received its
permanent adult-use and medical-use cannabis retailer license for its
dispensary in Sacramento, as well as temporary licenses for distribution
and cultivation. The tenant expects to be issued its permanent cannabis
cultivation license at the property upon completion of the property
redevelopment.

California, with nearly 40 million residents, was the first state to
permit the use of cannabis for medicinal purposes, adopting the
Compassion Care Act in 1996. In November 2016, California voters
approved the Adult Use of Marijuana Act (Proposition 64), which permits
the sale of cannabis for adult-use, with first licenses issued in 2018.
ArcView Market Research estimates that California regulated cannabis
spending will grow from approximately $2.5 billion in 2018 to $5.6
billion in 2022, just modestly below Canada’s total estimated regulated
cannabis spending in that year of $5.9 billion.

As of February 8, 2019, IIP owned twelve properties located in Arizona,
California, Colorado, Illinois, Maryland, Massachusetts, Michigan,
Minnesota, New York and Pennsylvania, totaling approximately 1,070,000
rentable square feet (including approximately 101,000 rentable square
feet under development/redevelopment), which were 100% leased with a
weighted-average remaining lease term of approximately 14.3 years. As of
February 8, 2019, IIP had invested approximately $156.3 million in the
aggregate (excluding transaction costs) and had committed an additional
approximately $22.6 million to reimburse certain tenants and sellers for
completion of construction and tenant improvements at IIP’s properties.
IIP’s average current yield on invested capital is approximately 15.2%
for these twelve properties, calculated as (a) the sum of the current
base rents, supplemental rent (with respect to the lease with PharmaCann
LLC at one of IIP’s New York properties) and property management fees,
divided by (b) IIP’s aggregate investment in these properties (excluding
transaction costs and including aggregate potential
development/redevelopment funding and tenant reimbursements of
approximately $22.6 million).

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is a self-advised Maryland
corporation focused on the acquisition, ownership and management of
specialized industrial properties leased to experienced, state-licensed
operators for their regulated medical-use cannabis facilities.
Innovative Industrial Properties, Inc. has elected to be taxed as a real
estate investment trust, commencing with the year ended December 31,
2017. Additional information is available at www.innovativeindustrialproperties.com.

Innovative Industrial Properties
Forward-Looking Statements

This press release contains statements that IIP believes to be
“forward-looking statements” within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
statements other than historical facts, including, without limitation,
statements regarding the lease of the California property, the tenant
and the California regulated cannabis market, are forward-looking
statements. When used in this press release, words such as we “expect,”
“intend,” “plan,” “estimate,” “anticipate,” “believe” or “should” or the
negative thereof or similar terminology are generally intended to
identify forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed in, or implied by, such
statements.
Investors should not place undue reliance upon
forward-looking statements.
IIP disclaims any obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.

HID Global and Phunware Collaborate to Improve Wayfinding for Patients and Visitors within Hospitals

AUSTIN, Texas–(BUSINESS WIRE)–HID Global®, a worldwide leader in trusted identity
solutions, and Phunware, Inc. (NASDAQ: PHUN), a fully integrated
enterprise cloud platform for mobile that provides products, solutions,
data and services for brands worldwide, today announced their
collaboration to improve the experience for hospital patients and
visitors to find their way within medical facilities, using wayfinding
on their mobile phones. Wayfinding is indoor navigation to guide a
person step-by-step on the way to a desired destination.

“The combination of Phunware’s market-leading wayfinding and mobile
engagement capabilities with innovative HID Location Services will
ultimately revolutionize wayfinding within healthcare institutions,”
said Phunware co-founder and CEO Alan S. Knitowski. “It’s easy for
visitors and patients to get lost in hospitals, and every time they do
it puts appointment times and patient satisfaction at risk. With our
location-aware app on a mobile device, we equip the visitor to get
instant, turn-by-turn navigation that creates a better experience than
that which is currently available on the market.”

Phunware and HID are addressing the need of healthcare institutions to
deploy standardized technology to provide a better wayfinding and
visitor engagement experience inside the hospital, across campus and
even in parking lots.

“Wayfinding is one more application that we are integrating into HID’s
unified healthcare IoT solution to make it easier for healthcare systems
to manage a growing demand for automated and streamlined experiences,”
said Rom Eizenberg, Vice President of Sales, Bluvision, part of HID
Global. “With HID technologies, we have changed the location-aware
landscape, delivering location as a service. Now, healthcare
organizations can easily lay out the foundation for IoT applications,
such as wayfinding.”

HID’s healthcare IoT solution-enablement platform simplifies the
delivery of real-time location of clinicians, patients and devices. The
platform is enabled by Bluvision (part of HID Global).

Phunware’s Multiscreen-as-a-Service (MaaS) platform also
provides enterprise-level mobile wayfinding, engagement, data and more
for other vertical markets, including retail, residential, hospitality,
media and entertainment and more.

About Phunware, Inc

Phunware Inc. is the pioneer of Multiscreen-as-a-Service (MaaS), a fully
integrated enterprise cloud platform for mobile that provides companies
the products, solutions, data and services necessary to engage, manage
and monetize their mobile application portfolios and audiences globally
at scale. Phunware helps the world’s most respected brands create
category-defining mobile experiences, with more than one billion active
devices touching its platform each month. For more information about how
Phunware is transforming the way consumers and brands interact with
mobile in the virtual and physical worlds, visit www.phunware.com,
www.phuncoin.com
and follow @phunware on all social media platforms.

About HID Global

HID Global powers the trusted identities of the world’s people, places
and things. We make it possible for people to transact safely, work
productively and travel freely. Our trusted identity solutions give people convenient
access to physical and digital places and connect things that
can be identified, verified and tracked digitally. Millions of people
around the world use HID products and services to navigate their
everyday lives, and over 2 billion things are connected through HID
technology. We work with governments, educational institutions,
hospitals, financial institutions, industrial businesses and some of the
most innovative companies on the planet. Headquartered in Austin, Texas,
HID Global has over 3,000 employees worldwide and operates international
offices that support more than 100 countries. HID Global® is an ASSA
ABLOY Group brand. For more information, visit www.hidglobal.com.

Stay Connected with HID Global

Visit our Media
Center
, read our Industry
Blog
, and follow us on FacebookLinkedIn and Twitter.

© 2019. HID Global Corporation/ASSA ABLOY AB. All rights reserved. HID,
HID Global, the HID Blue Brick logo, the Chain Design and Bluvision are
trademarks or registered trademarks of HID Global, ASSA ABLOY AB, or its
affiliates(s) in the US and other countries and may not be used without
permission. All other trademarks, service marks, and product or service
names are trademarks or registered trademarks of their respective owners.

Kugler Vision Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

OMAHA, Neb.–(BUSINESS WIRE)–Lance Kugler, M.D. at Kugler
Vision
in Omaha, Neb., is participating in the AcuFocus clinical
study for the IC-8 intraocular lens (IOL) designed for patients with
cataracts.

“We work with cataract patients each day and many ask if their surgery
will help them regain not only their distance vision, but also their
intermediate and near vision,” Dr.
Kugler
said. “We look forward to evaluating the IC-8 lens and its
ability to provide cataract patients with an uninterrupted range of
vision.”

By the age of 65, an estimated 90% of people worldwide experience
changes to the natural crystalline lens of the eye. The lens gradually
becomes cloudy as a cataract develops, leading to blurry vision and
eventually vision loss. The only solution to a cataract is the surgical
removal of the natural lens and its replacement with an artificial lens
called an IOL. More than 25 million cataract procedures are performed
worldwide each year. The majority of patients with cataracts are treated
with a standard monofocal (single-focus) lens, which allows the patient
to have excellent far vision; however, patients remain dependent on
glasses for near and intermediate vision.

Dr. Kugler will be one of a select group of clinical investigators
across the United States for the IC-8
lens study
. The IC-8 lens is a clear monofocal lens with a mini-ring
placed in the center. The mini-ring has an opening, or pinhole, designed
to increase the range of vision by extending the focus of light rays
that enter the eye. The clinical study will determine if the IC-8 lens
in one eye, when paired with a standard monofocal lens in the other eye,
will provide near and intermediate vision in addition to far vision for
cataract patients.

Kugler Vision is now enrolling patients that meet the study eligibility
criteria. Patients who comply with study commitments will be
compensated. Some basic qualifications include the following:

  • At least 22 years of age.
  • Have cataracts in both eyes.
  • Are available, willing and able to participate in examinations and all
    follow-up study visits and appointments.

If you are interested in becoming a volunteer participant in the IC-8
lens clinical study, please contact Jolene Palmquist at Kugler Vision at
(402) 558-2211 or at jpalmquist@kuglervision.com.

About Kugler Vision

Kugler
Vision
is a world-class refractive surgery center, making Omaha a
destination for exceptional vision correction outcomes. As a
patient-centric practice, we specialize in procedures to reduce or
eliminate reliance on glasses and contacts.

kuglervision.com
Facebook
Twitter
Instagram
17838
Burke St., Ste. 100, Omaha, NE 68118
402.558.2211

ABOUT ACUFOCUS THE IC-8 IOL

AcuFocus, Inc., is a privately held ophthalmic medical device company
that develops and markets breakthrough technologies for the improvement
of vision. The IC-8 lens received its CE mark in 2014 and is available
in select markets across Europe and Asia. Founded in 2001, AcuFocus is
based in Irvine, Calif. For additional information about the IC-8
intraocular lens, visit www.ic8lensclinicalstudy.com
or https://www.facebook.com/ic8lensclinicalstudy.

Caution: Investigational Device. Limited by Federal (or United States)
law to investigational use.